EAM Investors LLC Makes New $869,000 Investment in Codexis, Inc. (NASDAQ:CDXS)

EAM Investors LLC acquired a new stake in Codexis, Inc. (NASDAQ:CDXS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 182,223 shares of the biotechnology company's stock, valued at approximately $869,000. EAM Investors LLC owned 0.22% of Codexis as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Summit Investment Advisors Inc. raised its stake in Codexis by 81.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 3,783 shares during the period. Kingswood Wealth Advisors LLC acquired a new stake in Codexis during the fourth quarter worth approximately $79,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Codexis during the fourth quarter worth approximately $82,000. Intech Investment Management LLC grew its position in shares of Codexis by 55.1% in the fourth quarter. Intech Investment Management LLC now owns 33,111 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 11,757 shares during the last quarter. Finally, Corebridge Financial Inc. increased its stake in shares of Codexis by 7.2% during the fourth quarter. Corebridge Financial Inc. now owns 40,052 shares of the biotechnology company's stock worth $191,000 after purchasing an additional 2,703 shares during the period. 78.54% of the stock is currently owned by institutional investors.

Codexis Stock Performance

CDXS traded up $0.06 during trading on Tuesday, hitting $2.19. The stock had a trading volume of 141,340 shares, compared to its average volume of 656,831. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. The firm has a market cap of $181.00 million, a price-to-earnings ratio of -2.51 and a beta of 2.35. The company has a 50 day moving average price of $2.89 and a 200-day moving average price of $3.84. Codexis, Inc. has a one year low of $1.90 and a one year high of $6.08.

Codexis (NASDAQ:CDXS - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.09). The business had revenue of $21.46 million for the quarter, compared to the consensus estimate of $27.41 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. As a group, research analysts predict that Codexis, Inc. will post -0.77 EPS for the current year.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.